Genetic testing and personal genomics company providing health and ancestry insights.
23andMe Holding Co. is a pioneering consumer genetics testing company that operates in two distinct segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a comprehensive suite of genetic reports derived from customers' saliva samples using the company's spit kit. These reports include detailed information on genetic ancestral origins, personal health risks based on genetic markers, and the likelihood of passing on certain rare genetic conditions to offspring. Additionally, the segment offers insights into how genetic variations can impact responses to medications.
In parallel, the Therapeutics segment focuses on drug development and the discovery of novel therapies aimed at enhancing patient outcomes across diverse therapeutic areas such as oncology, respiratory conditions, and cardiovascular diseases. This segment also engages in out-licensing intellectual property associated with identified drug targets linked to ongoing clinical development efforts. Notably, 23andMe Holding Co. has entered into a strategic collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and commercialize innovative drugs.
Founded in 2006 and headquartered in South San Francisco, California, 23andMe Holding Co. stands at the forefront of integrating genetic information into personalized healthcare solutions. The company's commitment to advancing both consumer genetic testing services and therapeutic discoveries underscores its mission to empower individuals with valuable genetic insights while contributing to the advancement of precision medicine and drug development initiatives worldwide.
Through its innovative approach and strategic partnerships, 23andMe Holding Co. continues to shape the future of healthcare by harnessing the power of genetics to drive meaningful advancements in both consumer health and therapeutic innovation.